| 2024-11-13 | +0.03 % |
|
| 2024-11-12 | +0.44 % |
|
| 2024-11-08 | -0.47 % |
|
| 2024-11-07 | -1.34 % |
|
| 2024-11-06 | +1.15 % |
|
| 2024-11-01 | +0.33 % |
|
| 2024-10-31 | -2.63 % |
|
| 2024-10-30 | +5.71 % |
|
| 2024-10-29 | +0.27 % |
|
| 2024-10-28 | +1.22 % |
|
| 2024-10-24 | -0.67 % |
|
| 2024-10-22 | -0.89 % |
|
| 2024-10-16 | +0.82 % |
|
| 2024-10-15 | -0.22 % |
|
| 2024-10-14 | +1.29 % |
|
| 2024-10-09 | +1.66 % |
|
| 2024-10-08 | -0.5 % |
|
| 2024-10-03 | -1.42 % |
|
| 2024-10-02 | -1.54 % |
|
| 2024-10-01 | -0.57 % |
|
| 2024-09-30 | -0.25 % |
|
| 2024-09-27 | +0.47 % |
|
| 2024-09-26 | +1.14 % |
|
| 2024-09-25 | -1.22 % |
|
| 2024-09-17 | -1.11 % |
|
| 2024-09-13 | +1.07 % |
|
| 2024-09-09 | +0.02 % |
|
| 2024-09-05 | -8.74 % |
|
| 2024-09-03 | +0.61 % |
|
| 2024-08-14 | -0.62 % |
|
| 2024-08-07 | -3.43 % |
- Zimmer Biomet (ZBH) stock fell 3.43% due to ongoing market volatility and investors' concerns over sector performance amid the broader economic challenges influenced by geopolitical tensions and recovery in the US dollar.
- The article discusses the recent movements in the global markets and highlights that Zimmer Biomet (ZBH) stock fell by 3.43%, primarily due to broader market volatility and concerns regarding performance as it was set to report earnings amid a shaky tech sector.
- The article discusses Zimmer Biomet Holdings, Inc.'s announcement of its acquisition of OrthoGrid Systems, a company specializing in AI-driven surgical guidance, despite a recent 3.43% drop in its stock price. The decline in Zimmer Biomet's stock could be attributed to broader market movements, investor sentiment regarding the acquisition's immediate financial impact, or concerns about its integration and potential execution risks associated with the acquisition.
- Zimmer Biomet (ZBH) stock fell by 3.43% amidst a volatile market environment, potentially reflecting investor concerns related to overall market instability and earnings season uncertainties.
- Zimmer Biomet Holdings Inc. (ZBH) stock fell 3.43% after a Stifel analyst lowered the price target from $135 to $130, despite maintaining a Buy rating, due to mixed performance in the second quarter of 2024, highlighted by unexpectedly soft implant volumes early in the quarter.
|
| 2024-08-06 | +2.36 % |
|
| 2024-07-18 | +0.31 % |
|
| 2024-07-15 | -1.99 % |
|
| 2024-06-12 | -4.81 % |
|
| 2024-06-11 | -3.23 % |
- The article discusses the recent insider sale of NeuroOne Medical Technologies Corp's (NASDAQ: NMTC) stock by Business Development Director Mark Christianson, while highlighting the company's financial performance, revenue increases, and partnerships with organizations like Zimmer Biomet. The decline in NMTC's stock price may be attributed to concerns regarding the company's revenue decline, negative gross profit margin, and the perception that it is trading at a premium relative to its book value, as revealed by InvestingPro data.
- Zimmer Biomet (ZBH) stock was down 3.23% last night due to analysts revising earnings expectations downwards, despite the company's strategic partnership with THINK Surgical for a TMINI Miniature Robotic System for knee arthroplasty, as Zimmer Biomet expands its robotic offerings and looks to enhance its ROSA® Robotics suite with innovative technology and partnerships in the medical field.
- Zimmer Biomet's stock was down 3.23% last night following the announcement of a limited distribution agreement with THINK Surgical, Inc. for its TMINI Miniature Robotic System for total knee arthroplasty, as the company expands its robotics portfolio, integrating Zimmer Biomet technology into a new robotic solution.
|
| 2024-06-07 | -0.03 % |
|
| 2024-06-04 | +0.28 % |
|
| 2024-05-31 | +0.62 % |
|
| 2024-05-30 | -0.61 % |
|
| 2024-05-29 | -1.02 % |
- The article mentions that Zimmer Biomet (ZBH) stock was down by -1.02% last night, and the overall market saw mixed movements with various stocks going up and down; the reason for Zimmer Biomet's stock decrease was not explicitly provided in this summary.
- Summary: Zimmer Biomet Holdings (ZBH) announced a partnership with CBRE Group to develop orthopedic ambulatory surgery centers, introduced a $2 billion stock repurchase program, and unveiled a financial strategy aiming for mid-single-digit revenue growth and shareholder returns through 2027.
Reason for stock decline: The Zimmer Biomet (ZBH) stock may have decreased due to general market conditions, profit-taking by investors, or external factors impacting the healthcare sector.
- The article is about Zimmer Biomet Holdings, Inc.'s 2024 Investor Day presentation, highlighting the company's strategic priorities and long-range plan for growth and value creation, including a new partnership with CBRE to develop orthopedic ambulatory surgery centers in the U.S. Zimmer Biomet (ZBH) stock went down last night possibly due to market factors, investor sentiment, or reactions to the company's announcements during the Investor Day.
|
| 2024-05-28 | -0.07 % |
|
| 2024-05-20 | -0.94 % |
|
